Narcolepsy (Central Nervous System) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Narcolepsy – Drugs In Development, 2021, provides an overview of the Narcolepsy (Central Nervous System) pipeline landscape.Narcolepsy is a sleep disorder that causes excessive sleepiness and frequent daytime sleep attacks. Symptoms of narcolepsy include excessive daytime sleepiness (EDS), cataplexy, hallucinations and sleep paralysis. Narcolepsy treatment includes lifestyle change, medication and counseling.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Narcolepsy – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Narcolepsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Narcolepsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Narcolepsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 2, 6, 8, 7 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Narcolepsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Narcolepsy (Central Nervous System).- The pipeline guide reviews pipeline therapeutics for Narcolepsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. – The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.- The pipeline guide reviews key companies involved in Narcolepsy (Central Nervous System) therapeutics and enlists all their major and minor projects.- The pipeline guide evaluates Narcolepsy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. – The pipeline guide reviews latest news related to pipeline therapeutics for Narcolepsy (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.- Find and recognize significant and varied types of therapeutics under development for Narcolepsy (Central Nervous System).- Classify potential new clients or partners in the target demographic.- Develop tactical initiatives by understanding the focus areas of leading companies.- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.- Formulate corrective measures for pipeline projects by understanding Narcolepsy (Central Nervous System) pipeline depth and focus of Indication therapeutics.- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Avadel Pharmaceuticals Plc

Axsome Therapeutics Inc

Balance Therapeutics Inc

Bioprojet SCR

Centessa Pharmaceuticals Plc

F. Hoffmann-La Roche Ltd

Gubra ApS

Inexia Ltd

Jazz Pharmaceuticals Plc

NLS Pharma Group

Ono Pharmaceutical Co Ltd

Seelos Therapeutics, Inc.

SK Biopharmaceuticals Co Ltd

Suven Life Sciences Ltd

Synchronicity Pharma Inc

Takeda Pharmaceutical Co Ltd

Theranexus SAS

Vallon Pharmaceuticals Inc

XWPharma Ltd

Table of Contents

Table of Contents

Introduction

Narcolepsy - Overview

Narcolepsy - Therapeutics Development

Narcolepsy - Therapeutics Assessment

Narcolepsy - Companies Involved in Therapeutics Development

Narcolepsy - Drug Profiles

Narcolepsy - Dormant Projects

Narcolepsy - Discontinued Products

Narcolepsy - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Narcolepsy, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Narcolepsy – Pipeline by Avadel Pharmaceuticals Plc, 2021

Narcolepsy – Pipeline by Axsome Therapeutics Inc, 2021

Narcolepsy – Pipeline by Balance Therapeutics Inc, 2021

Narcolepsy – Pipeline by Bioprojet SCR, 2021

Narcolepsy – Pipeline by Centessa Pharmaceuticals Plc, 2021

Narcolepsy – Pipeline by F. Hoffmann-La Roche Ltd, 2021

Narcolepsy – Pipeline by Gubra ApS, 2021

Narcolepsy – Pipeline by Inexia Ltd, 2021

Narcolepsy – Pipeline by Jazz Pharmaceuticals Plc, 2021

Narcolepsy – Pipeline by NLS Pharma Group, 2021

Narcolepsy – Pipeline by Ono Pharmaceutical Co Ltd, 2021

Narcolepsy – Pipeline by Seelos Therapeutics, Inc., 2021

Narcolepsy – Pipeline by SK Biopharmaceuticals Co Ltd, 2021

Narcolepsy – Pipeline by Suven Life Sciences Ltd, 2021

Narcolepsy – Pipeline by Synchronicity Pharma Inc, 2021

Narcolepsy – Pipeline by Takeda Pharmaceutical Co Ltd, 2021

Narcolepsy – Pipeline by Theranexus SAS, 2021

Narcolepsy – Pipeline by Vallon Pharmaceuticals Inc, 2021

Narcolepsy – Pipeline by XWPharma Ltd, 2021

Narcolepsy – Dormant Projects, 2021

Narcolepsy – Dormant Projects, 2021 (Contd..1)

Narcolepsy – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Narcolepsy, 2021

Number of Products under Development by Companies, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports